Leads Biolabs And Dianthus Therapeutics Announce Initiation of Phase 1 Trial Of LBL-047 (DNTH212) In Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE) [Yahoo! Finance]
Leads Biolabs And Dianthus Therapeutics Announce Initiation of Phase 1 Trial Of LBL-047 (DNTH212) In Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE)
Dianthus Therapeutics (NASDAQ:DNTH) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $46.00 price target on the stock.
Ashland, Bitdeer, and More Stocks See Action From Activist Investors [Yahoo! Finance]
Dianthus Therapeutics To Participate in the 8th Annual Evercore Healthcare Conference